HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo

Blood

Volumn 117, Issue 20, 2011, Pages 5391-5402

  Chapuis, Aude G ^a   Casper, Corey ^a   Kuntz, Steve ^a   Zhu, Jia ^a   Tjernlund, Annelie ^a,b   Diem, Kurt ^a   Turtle, Cameron J ^a   Cigal, Melinda L ^a   Velez, Roxanne ^a   Riddell, Stanley ^a   Corey, Lawrence ^a   Greenberg, Philip D ^a  

^a USA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ANTIRETROVIRUS AGENT; BETA7 INTEGRIN; CD103 ANTIGEN; CD11B ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; GAMMA INTERFERON; INTERLEUKIN 2; PADGEM PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE LYMPHATIC TISSUE; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECTUM MUCOSA; UPREGULATION; VIRUS INHIBITION;

EID: 79956338434     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-320226     Document Type: Article

References (50)

1. Mollet L, Li TS, Samri A, et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol. 2000;165(3):1692-1704. (Pubitemid 30604609)
2. Haase AT. Perils at mucosal front lines for HIV and SIVand their hosts. Nat Rev Immunol. 2005;5(10):783-792. (Pubitemid 41400852)
3. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS. 2000;14(12):1761-1765.
4. Lapenta C, Boirivant M, Marini M, et al. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol. 1999;29(4):1202-1208. (Pubitemid 29164166)
5. Talal AH, Monard S, Vesanen M, et al. Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue. J Acquir Immune Defic Syndr. 2001;26(1):1-7. (Pubitemid 32115045)
6. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol. 2006;80(16):8236-8247. (Pubitemid 44182323)
7. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3(12): e484.
8. Frenkel LM, Wang Y, Learn GH, et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol. 2003;77(10):5721-5730. (Pubitemid 36538965)
9. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol. 2008;122(1):22-28. (Pubitemid 351899083)
10. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407(6803):523-526.
11. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283(5403):857-860.
12. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8 (+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189(6):991-998. (Pubitemid 29149355)
13. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68(7):4650-4655. (Pubitemid 24183063)
14. Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virusspecific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy J Virol. 2001;75(14):6508-6516. (Pubitemid 32578170)
15. Dorrell L. Therapeutic immunization for the control of HIV-1: where are we now? Int J STD AIDS. 2006;17(7):436-441; quiz 442.
16. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A. 2002;99(21):13747- 13752. (Pubitemid 35215452)
17. Autran B, Murphy RL, Costagliola D, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS. 2008;22(11):1313-1322.
18. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238-241.
19. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med. 1999;5(1):34-41. (Pubitemid 29050996)
20. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T cell subsets in response to antigen or homeostatic cytokines. Blood. 2003;101(11):4260-4266. (Pubitemid 36857786)
21. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294-305.
22. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225-234. (Pubitemid 36322131)
23. Rufer N, Zippelius A, Batard P, et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood. 2003;102(5):1779-1787. (Pubitemid 37022574)
24. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708-712.
25. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379-385. (Pubitemid 34407033)
26. Rehr M, Cahenzli J, Haas A, et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol. 2008;82(27):3391-3404. (Pubitemid 351429916)
27. Kern F, Surel IP, Faulhaber N, et al. Target structures of the CD8 (+)-T cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol. 1999;73(10):8179-8184. (Pubitemid 29441679)
28. Frahm NB, B. Brander, C. Identification and optimal definition of HIV-derived cytotoxic T lymphocytes (CTL) epitopes for the study of CTL escape, functional avidity and viral evolution. In: Korber BB, Haynes B, Koup B, Moore R, Walker J, Watkins D, eds. HIV Molecular Immunology 2008. Los Alamos, NM: Los Alamos National Laboratory, Theoretical Biology and Biophysics. 2008;3-24.
29. Yee C, Thompson JA, Byrd D, et al. AdoptiveT cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99(25):16168-16173. (Pubitemid 35462767)
30. Monteiro J, Hingorani R, Choi IH, Silver J, Pergolizzi R, Gregersen PK. Oligoclonality in the human CD8+ Tcell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases. Mol Med. 1995;1(6):614-624.
31. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196(10):1500-1508. (Pubitemid 351411987)
32. Papagno L, Almeida JR, Nemes E, Autran B, Appay V. Cell permeabilization for the assessment of T lymphocyte polyfunctional capacity. J Immunol Methods. 2007;328 (1-2): 182-188. (Pubitemid 350017756)
33. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274(5284):94-96. (Pubitemid 26332731)
34. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007;204(3):595-603. (Pubitemid 46457082)
35. Tjernlund A, Zhu J, Laing K, et al. In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques. Retrovirology 2010;7:12.
36. Bolton DL, Minang JT, Trivett MT, et al. Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous simian immunodeficiency virus-specific CD8 (+) T cell clones during acute and chronic infection of rhesus macaques. J Immunol. 2010;184(1):303-314.
37. Minang JT, Trivett MT, Bolton DL, et al. Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8 (+) T cell clones in rhesus macaques during acute infection. J Immunol. 2010;184(1):315-326.
38. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8T cells support CD4-independent proliferation of HIV-1-specific CD8T cells. Proc Natl Acad Sci USA. 2005;102 (20) 7239-7244. (Pubitemid 40696363)
39. Betts MR, Nason MC, West SM, et al. HIVnonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781-4789. (Pubitemid 43882629)
40. Ahmed R, Bevan MJ, Reiner SL, Fearon DT. The precursors of memory: models and controversies. Nat Rev Immunol. 2009;9(9):662-668.
41. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251-262. (Pubitemid 37323225)
42. Ragheb JA, Deen M, Schwartz RH. CD28-mediated regulation of mRNAstability requires sequences within the coding region of the IL-2 mRNA. J Immunol. 1999;163(1):120-129. (Pubitemid 29295832)
43. Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD. Restoration of CD28 expression in CD28-CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med. 2003;198(6):947-955. (Pubitemid 37152931)
44. Ndongala ML, Kamya P, Boulet S, et al. Changes in function of HIV-specific T cell responses with increasing time from infection. Viral Immunol. 2010;23(2):159-168.
45. Yu J, Chen H, Horton H, et al. Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ Tcell proliferation in HIV infection. J Med Virol. 2006;78(9):1147-1157. (Pubitemid 44182230)
46. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105(1):241-250. (Pubitemid 40053089)
47. Ochsenbein AF, Riddell SR, Brown M, et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med. 2004;200(11):1407-1417. (Pubitemid 39657288)
48. Zeitz M, Ullrich R, Schneider T, Kewenig S, Riecken E. Mucosal immunodeficiency in HIV/SIV infection. Pathobiology 1998;66 (3-4): 151-157. (Pubitemid 28336403)
49. Gandhi RT, O'Neill D, Bosch RJ, et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009;27(43):6088- 6094.
50. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(6):247-258. (Pubitemid 351432801)